Minimal Residual Disease Monitoring Using a 3 ′ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma

In ALK-positive anaplastic large-cell lymphomas, positive qualitative PCR for NPM1-ALK in peripheral blood and/or bone marrow at diagnosis and during treatment are associated with a higher risk of treatment failure. Real-time quantitative PCR allows identification of very high risk patients. However, this latter technique initially designed for patients with lymphomas carrying the most frequent NPM1-ALK translocation necessitates calibration curves, limiting interlaboratory reproducibility. We designed an ALK universal quantitative PCR based on 3 ′ALK transcript amplification to allow the detection of all ALK fusion transcripts.

Source: Journal of Molecular Diagnostics - November 23, 2020 Category: Pathology Authors: Cathy Quelen, David Grand, Emeline Sarot, Laurence Brugi ères, David Sibon, Anne Pradines, Camille Laurent, Pierre Brousset, Laurence Lamant Tags: Technical advance Source Type: research